Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 28, 2008 Brian Orelli	Wyeth Fires to Get Back on Fire The first round of Wyeth's cuts look like the right move for the big pharma company.
The Motley Fool September 22, 2008 Brian Orelli	Let's Bail Out Pharma Next Schering-Plough is cutting jobs. Maybe the government should help out?
The Motley Fool December 1, 2009 Brian Orelli	Abbott Makes All the Right Moves Hot off its cholesterol win over Merck, Abbott Labs is playing it safe with another cholesterol drug, TriCor.
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool April 4, 2008 Brian Orelli	Why Is Schering Cutting Now? The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough.
The Motley Fool April 23, 2008 Brian Orelli	Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
The Motley Fool December 18, 2008 Brian Orelli	A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
The Motley Fool May 6, 2008 Brian Orelli	A Sign of the Pharma Times Merck is the latest big pharma cutting jobs to improve its bottom line.
The Motley Fool March 20, 2008 Brian Orelli	Abbott and Takeda's Partnership TAPed Out It looks like Abbott Laboratories and Takeda will be ending their 30-year joint partnership with a 50/50 split.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool March 31, 2008 Brian Orelli	No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating.
The Motley Fool June 21, 2005 Brian Gorman	Wyeth's Lower Dosage The company's planned sales-force cutback shows its resolve to increase efficiency. Investors, this pharmaceutical remains the one to watch.
The Motley Fool April 29, 2009 Brian Orelli	The Other 33.1% of Pfizer Reports The take-home message for current and future Pfizer shareholders from Wyeth's quarterly report is that they're not getting a growth monster, but Wyeth's revenue is fairly stable.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool January 20, 2009 Brian Orelli	Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue.
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool December 30, 2008 Brian Orelli	A Post-Holiday Breakup ... of Sorts Abbott and Celera revise their partnership.
The Motley Fool September 5, 2008 Brian Orelli	Zimmer Fortifies Its Spine The medical-device maker is buying Abbott's spine business.
The Motley Fool July 25, 2008 Brian Orelli	Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool October 14, 2008 Brian Orelli	Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.
The Motley Fool July 15, 2009 Brian Orelli	Less Inflammation From Abbott's Quarter Humira is headed back in the right direction.
The Motley Fool May 19, 2009 Brian Orelli	The Cherry on Pfizer's Acquisition Sundae Pfizer may inherit a lawsuit.
The Motley Fool January 19, 2012 Sean Williams	No Vacancy: Workers Need Not Apply to This Sector Pharmaceutical and biotech layoffs are kicking into high gear.
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
Chemistry World August 3, 2011 Patrick Walter	Merck Continues Restructuring and Cuts 13,000 Jobs US drug giant Merck & Co will lay off as much as 13 per cent of its workforce - up to 13,000 staff - by the end of 2015. The move is part of an aggressive cost cutting drive to streamline the company.
The Motley Fool September 22, 2008 Brian Orelli	Ouch, That's Gotta Hurt! Acupuncture beats Wyeth's Effexor in stopping hot flashes.
BusinessWeek January 29, 2007 Michael Arndt	Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade.
The Motley Fool January 23, 2009 Brian Orelli	Wyeth Isn't Cheap Enough for Pfizer The Wall Street Journal reports that Pfizer is in talks to acquire Wyeth for $60 billion or more. Should they do it?
The Motley Fool December 16, 2008 Brian Orelli	Doubling Up on Triple Lipid Drugs The Food and Drug Administration gave Abbott Lab's TriLipix the thumbs-up, approving it for use by itself or with statins.
The Motley Fool August 28, 2008 Brian Orelli	Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy.
The Motley Fool July 19, 2006 Stephen D. Simpson	No Vow of Poverty for This Abbott Abbott Labs delivers a solid quarter with broad-based growth. Investors, the stock is moderately undervalued and likely to be a worthwhile long-term holding.
The Motley Fool February 4, 2008 Chuck Saletta	Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker.
The Motley Fool July 19, 2007 Brian Lawler	Abbott on Top Abbott announces second-quarter financial results. Shares of Abbott aren't particularly expensive, considering the growth potential for its top compounds and its strong drug pipeline with compounds in development for several blockbuster indications.
The Motley Fool August 4, 2010 Matt Koppenheffer	How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale?
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool May 22, 2008 Brian Orelli	Wyeth's Never-Ending Generic Woes Novartis jumps on the generic Protonix bandwagon.
The Motley Fool December 26, 2007 Brian Orelli	Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute.
The Motley Fool January 23, 2007 Ralph Casale	Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note.